Patents by Inventor Aaron Bayne Miller

Aaron Bayne Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Furin inhibitors
    Patent number: 11773078
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 3, 2023
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
  • FURIN INHIBITORS
    Publication number: 20220315556
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 6, 2022
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7799828
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: September 21, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Naphthalene compounds as selective estrogen receptor modulators
    Patent number: 7649093
    Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Smith Kline LLC
    Inventors: Dennis Heyer, Jing Fang, Frank Navas, III, Subba Reddy Katamreddy, Jennifer Poole Peckham, Philip Stewart Turnbull, Aaron Bayne Miller, Adwoa Akwabi-Ameyaw
  • Cycloalkylidene Compounds As Modulators of Estrogen Receptor
    Publication number: 20090253659
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Application
    Filed: June 8, 2009
    Publication date: October 8, 2009
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, JR., William J. Zuercher, Subba Reddy Katamreddy
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7569601
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 4, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7560589
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jonathan E. Britton, Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Substituted quinoline compounds for use as selective estrogen receptor modulator
    Patent number: 7405303
    Abstract: The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: July 29, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: William Joel Hoekstra, Aaron Bayne Miller, William John Zuercher, Harikrishna Suryakant Patel
  • Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss
    Patent number: 7402606
    Abstract: Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: July 22, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: David Gene Barrett, John G. Catalano, David Norman Deaton, Aaron Bayne Miller, John A. Ray, Vicente Samano
  • Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
    Patent number: 7282512
    Abstract: Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: October 16, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: John George Catalano, David Norman Deaton, Aaron Bayne Miller, Francis Xavier Tavares
  • Selective RXR ligands
    Patent number: 7173134
    Abstract: The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR?, RXR?, or RXR?. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: February 6, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Curt Dale Haffner, Istvan Kaldor, Darryl Lynn McDougald, Aaron Bayne Miller
  • 1-phenylalkanone 5-HT.sub.4 receptor ligands
    Patent number: 5763458
    Abstract: The present invention relates to novel 5-HT.sub.4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C.sub.2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C.sub.1-4)alkyloxy or phenyl(C.sub.1-4)alkyloxy and optionally substituted at its 3-position with (C.sub.1-4)alkyloxy or substituted at its 2- and 3-positions together with methylenedioxy or ethylenedioxy and the highest numbered carbon of the (C.sub.2-6)alkan-1-one is substituted with di(C.sub.1-4)alkylamino, morpholin-1-yl or pyrrolidin-1-yl or optionally substituted piperidin-1-yl, piperidin-4-yl, azacyclohept-1-yl, azabicyclo?2.2.1!hept-3-yl, azabicylo?2.2.2!oct-3-yl or azabicylo?3.2.2!non-3-yl; and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers and methods of using and making such derivatives.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 9, 1998
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin Douglas Clark, Richard Malcolm Eglen, John Otis Gardner, Alam Jahangir, Aaron Bayne Miller